Wall Street brokerages forecast that Albireo Pharma Inc (NASDAQ:ALBO) will announce earnings of ($1.44) per share for the current quarter, according to Zacks. Four analysts have provided estimates for Albireo Pharma’s earnings, with the highest EPS estimate coming in at ($1.33) and the lowest estimate coming in at ($1.61). Albireo Pharma reported earnings per share of ($1.22) during the same quarter last year, which suggests a negative year-over-year growth rate of 18%. The company is expected to report its next earnings results on Tuesday, August 6th.
On average, analysts expect that Albireo Pharma will report full-year earnings of ($5.99) per share for the current year, with EPS estimates ranging from ($6.68) to ($5.54). For the next year, analysts expect that the firm will post earnings of ($5.27) per share, with EPS estimates ranging from ($5.77) to ($4.61). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Albireo Pharma.
Albireo Pharma (NASDAQ:ALBO) last issued its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($1.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.37) by ($0.02). The company had revenue of $0.57 million during the quarter, compared to the consensus estimate of $1.20 million. Albireo Pharma had a negative net margin of 2,900.81% and a negative return on equity of 47.03%.
Several brokerages recently commented on ALBO. BidaskClub downgraded shares of Albireo Pharma from a “hold” rating to a “sell” rating in a research note on Sunday. ValuEngine cut shares of Albireo Pharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Wedbush set a $69.00 price target on shares of Albireo Pharma and gave the company a “buy” rating in a research report on Thursday, May 23rd. Zacks Investment Research upgraded shares of Albireo Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Finally, William Blair restated an “outperform” rating on shares of Albireo Pharma in a research report on Thursday, May 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $54.25.
NASDAQ:ALBO traded up $0.48 on Wednesday, hitting $31.58. The company had a trading volume of 3,266 shares, compared to its average volume of 52,470. The stock has a market cap of $377.55 million, a PE ratio of -7.97 and a beta of 1.67. The company’s 50 day moving average price is $33.57. Albireo Pharma has a 52 week low of $19.10 and a 52 week high of $38.69.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp lifted its stake in Albireo Pharma by 8.6% during the third quarter. Bank of New York Mellon Corp now owns 35,023 shares of the biopharmaceutical company’s stock worth $1,154,000 after purchasing an additional 2,760 shares during the period. Rhumbline Advisers lifted its stake in Albireo Pharma by 40.2% during the fourth quarter. Rhumbline Advisers now owns 13,056 shares of the biopharmaceutical company’s stock worth $320,000 after purchasing an additional 3,743 shares during the period. Victory Capital Management Inc. lifted its stake in Albireo Pharma by 40.3% during the fourth quarter. Victory Capital Management Inc. now owns 72,190 shares of the biopharmaceutical company’s stock worth $1,771,000 after purchasing an additional 20,740 shares during the period. Prudential Financial Inc. lifted its stake in Albireo Pharma by 5.6% during the fourth quarter. Prudential Financial Inc. now owns 26,556 shares of the biopharmaceutical company’s stock worth $652,000 after purchasing an additional 1,404 shares during the period. Finally, Sectoral Asset Management Inc lifted its stake in Albireo Pharma by 21.3% during the fourth quarter. Sectoral Asset Management Inc now owns 229,978 shares of the biopharmaceutical company’s stock worth $5,641,000 after purchasing an additional 40,400 shares during the period. Hedge funds and other institutional investors own 70.41% of the company’s stock.
Albireo Pharma Company Profile
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.
See Also: Is a Roth IRA right for you?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.